Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21587654 | 1.00 | ALOX5 (0.31) | ALOX5 | |
| SCHEMBL22759733 | 0.84 | ALOX5 (0.35) | ALOX5 | |
| SCHEMBL22759851 | 0.81 | PNMT (0.31) | — | |
| SCHEMBL22747767 | 0.81 | PNMT (0.31) | — | |
| SCHEMBL22747780 | 0.81 | MAPKAPK2 (0.33) | — | |
| SCHEMBL22759610 | 0.81 | PNMT (0.31) | — | |
| SCHEMBL22759729 | 0.76 | ALOX5 (0.39) | ALOX5 | |
| SCHEMBL29237101 | 0.76 | ALOX5 (0.39) | ALOX5 | |
| SCHEMBL22759607 | 0.76 | OTUD7B (0.36) | — | |
| SCHEMBL22759850 | 0.76 | OTUD7B (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112204024-B | ERK inhibitor and application thereof | 贝达药业股份有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-11466013-B2 | ERK inhibitor and use thereof | BETTA PHARMACEUTICALS CO., LTD (CN) | 2022-10-11 | — | — | US | disclosed |
| EP-3805217-A1 | ERK INHIBITOR AND USE THEREOF | Betta Pharmaceuticals Co., Ltd (CN) | 2021-04-14 | — | — | EP | disclosed |
| CN-112204024-A | ERK inhibitor and application thereof | 贝达药业股份有限公司 | 2021-01-08 | — | — | CN | disclosed |
| CN-112204027-A | ERK inhibitor and application thereof | 贝达药业股份有限公司 | 2021-01-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11466013-B2 | ERK inhibitor and use thereof | MAPK1, MAPK4, MAPK7 | ALOX5 1804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.